Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma

PURPOSE: We developed polycaprolactone (PCL) implants that achieve zero-order release of a proprietary ocular hypotensive agent (DE-117) over 6 months. METHODS: The release rates of DE-117–loaded PCL devices were tuned based on an established predictive model and confirmed by in vitro release studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jean, Kudisch, Max, Mudumba, Sri, Asada, Hiroyuki, Aya-Shibuya, Eri, Bhisitkul, Robert B., Desai, Tejal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2016
Materias:
Glaucoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015984/
https://www.ncbi.nlm.nih.gov/pubmed/27556217
http://dx.doi.org/10.1167/iovs.16-19585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015984/
https://www.ncbi.nlm.nih.gov/pubmed/27556217
http://dx.doi.org/10.1167/iovs.16-19585

Ejemplares similares